Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting
Key result
Baseline vitronectin ≥49.7 μg/mL was associated with increased odds of major adverse cardiovascular events at 6 months compared to lower levels (20.0% vs 6.2%; OR 3.36, 95% CI 1.33-8.52).
Why the study?
Does high baseline vitronectin concentration predict major adverse cardiovascular events in acute coronary syndrome patients undergoing coronary stenting?
Population
233 patients with acute coronary syndrome undergoing coronary stenting from the EPISTENT trial
Comparison
High baseline vitronectin concentration vs Lower baseline vitronectin concentration
Design
Cohort
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Overview
May support post-stenting risk stratification in ACS; hypothesis-generating and requires prospective validation before clinical use.
Study Design
Type
Cohort (n=233)
Structured PICO
Does high baseline vitronectin concentration predict major adverse cardiovascular events in acute coronary syndrome patients undergoing coronary stenting?
P
Population
233 patients with acute coronary syndrome undergoing coronary stenting, followed for up to 6 months.
E
Exposure
High baseline vitronectin concentration (≥49.7 μg/mL, upper quartile)
C
Comparator
Lower baseline vitronectin concentration (<49.7 μg/mL, 3 lower quartiles)
O
Outcome
Major adverse cardiovascular event defined as death, myocardial infarction or urgent revascularization at 30 days and 6 monthscomposite
Main Result
Odds Ratio: 3.36 (95% CI 1.33–8.52)
Absolute Event Rate: 20% vs 6.2%
p-value: p=0.006
High baseline vitronectin concentrations independently predict an increased risk of major adverse cardiovascular events in patients with acute coronary syndrome undergoing coronary stenting.
Cite This Study
Derer et al. (2008) conducted a cohort in Acute coronary syndrome (n=233). Baseline vitronectin ≥49.7 μg/mL vs. Baseline vitronectin <49.7 μg/mL was evaluated on Major adverse cardiovascular event (death, myocardial infarction, or urgent revascularization) at 6 months (OR 3.36, 95% CI 1.33-8.52, p=0.006). Baseline vitronectin ≥49.7 μg/mL was associated with increased odds of major adverse cardiovascular events at 6 months compared to lower levels (20.0% vs 6.2%; OR 3.36, 95% CI 1.33-8.52).